Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issues
This issue
22-3
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
22-3
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Index of Authors
Author #96256
advertisement
Kolomeyer NN
14
Showing records 1 to 14 |
Display all abstracts from
Kolomeyer NN
95667
Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Kolomeyer NN
Journal of Glaucoma
2021; 30: 875-877
95894
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Shiuey EJ
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 967-974
95667
Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Kolomeyer NN; Katz LJ
Journal of Glaucoma
2021; 30: 875-877
95894
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Mehran NA; Ustaoglu M
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 967-974
95667
Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Hark LA; Wahl M
Journal of Glaucoma
2021; 30: 875-877
95894
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Zhang Q
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 967-974
95667
Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Gajwani P
Journal of Glaucoma
2021; 30: 875-877
95894
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Razeghinejad R; Shukla AG
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 967-974
95667
Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Aziz K
Journal of Glaucoma
2021; 30: 875-877
95894
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Shukla AG
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 967-974
95667
Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Myers JS
Journal of Glaucoma
2021; 30: 875-877
95894
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Kolomeyer NN; Kolomeyer NN; Myers JS
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 967-974
95667
Lessons Learned From 2 Large Community-based Glaucoma Screening Studies
Friedman DS
Journal of Glaucoma
2021; 30: 875-877
95894
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Lee D
Graefe's Archive for Clinical and Experimental Ophthalmology
2022; 260: 967-974
Issue
22-3
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept